Clinical decision making in the treatment of mania.

Nine agents are now Food and Drug Administration-approved for acute treatment of bipolar mania, and several other agents are being studied for efficacy. With multiple treatment options available, clinicians face the challenge of selecting among agents. Although clinicians may consult the American Psychiatric Association's Practice Guideline for the Treatment of Patients With Bipolar Disorder, Second Edition, when selecting a treatment for bipolar mania, decisions about many aspects of treatment, such as choosing among agents, comparing combination therapy versus monotherapy, and individualizing treatments, remain complex. Considering data from recent clinical studies that have compared the efficacy, safety, and tolerability of medications for bipolar mania both between and within classes may facilitate such treatment decisions.

[1]  E. Vieta,et al.  Weight gain in bipolar disorder: pharmacological treatment as a contributing factor , 2008, Acta psychiatrica Scandinavica.

[2]  S. Beaulieu,et al.  Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain , 2008, CNS drugs.

[3]  H. Nasrallah,et al.  Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles , 2008, Molecular Psychiatry.

[4]  T. Pollmächer,et al.  Clozapine and Olanzapine Are Associated With Food Craving and Binge Eating: Results From A Randomized Double-Blind Study , 2007, Journal of clinical psychopharmacology.

[5]  W. Fleischhacker,et al.  Metabolic side effects of antipsychotic medication , 2007, International journal of clinical practice.

[6]  Tamra J. Courey.  Detection, Prevention, and Management of Extrapyramidal Symptoms , 2007 .

[7]  P. Weiden,et al.  Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. , 2007, The Journal of clinical psychiatry.

[8]  S. Leucht,et al.  Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. , 2007, Archives of general psychiatry.

[9]  P. Bria,et al.  Oxcarbazepine in bipolar disorder: a critical review of the literature , 2007, Expert opinion on pharmacotherapy.

[10]  R. Perlis.  Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians , 2007, Current medical research and opinion.

[11]  S. C. Stoner,et al.  Historical Review of Carbamazepine for the Treatment of Bipolar Disorder , 2007, Pharmacotherapy.

[12]  M. Tohen,et al.  Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. , 2006, The Journal of clinical psychiatry.

[13]  T. Wilens,et al.  A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. , 2006, The American journal of psychiatry.

[14]  P. Keck,et al.  Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. , 2006, The Journal of clinical psychiatry.

[15]  J. Calabrese,et al.  A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. , 2006, The Journal of clinical psychiatry.

[16]  E. Taylor,et al.  Treating Bipolar Disorders , 2006 .

[17]  P. Keck,et al.  Extended-Release Carbamazepine Capsules as Monotherapy in Bipolar Disorder , 2006, CNS drugs.

[18]  L. Ginsberg.  Carbamazepine extended-release capsules use in bipolar disorder: efficacy and safety in adult patients. , 2006, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[19]  E. Vieta,et al.  Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. , 2005, The British journal of psychiatry : the journal of mental science.

[20]  S. Potkin,et al.  Ziprasidone in Acute Bipolar Mania: A 21-Day Randomized, Double-Blind, Placebo-Controlled Replication Trial , 2005, Journal of clinical psychopharmacology.

[21]  G. Goodwin,et al.  Lithium – a continuing story in the treatment of bipolar disorder , 2005, Acta psychiatrica Scandinavica. Supplementum.

[22]  P. Keck,et al.  Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. , 2005, The Journal of clinical psychiatry.

[23]  H. Grunze,et al.  A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. , 2005, The Journal of clinical psychiatry.

[24]  J. Calabrese,et al.  Maintenance therapies in bipolar disorder: focus on randomized controlled trials. , 2005, The Australian and New Zealand journal of psychiatry.

[25]  R. Perlis.  The role of pharmacologic treatment guidelines for bipolar disorder. , 2005, The Journal of clinical psychiatry.

[26]  T. Ketter,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. , 2004, The Journal of clinical psychiatry.

[27]  H. Nasrallah.  Factors in Antipsychotic Drug Selection: Tolerability Considerations , 2003, CNS Spectrums.

[28]  P. Mitchell,et al.  Pharmacotherapy to limit weight gain caused by antipsychotic use , 2003, Expert opinion on pharmacotherapy.

[29]  G. Goodwin,et al.  Latest maintenance data on lithium in bipolar disorder , 2003, European Neuropsychopharmacology.

[30]  G. Sachs,et al.  A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. , 2002, The Journal of clinical psychiatry.

[31]  J. McIntyre.  Usefulness and limitations of treatment guidelines in psychiatry. , 2002, World psychiatry : official journal of the World Psychiatric Association.

[32]  M. Tohen,et al.  Olanzapine versus divalproex in the treatment of acute mania. , 2002, The American journal of psychiatry.

[33]  J. Calabrese,et al.  Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. , 2002, The Journal of clinical psychiatry.

[34]  M. Thase,et al.  Practice guideline for the treatment of patients with bipolar disorder (revision). , 2002, The American journal of psychiatry.

[35]  M. Tohen,et al.  Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study , 2001, European Neuropsychopharmacology.

[36]  M. Berk,et al.  Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. , 1999, International clinical psychopharmacology.

[37]  M. Berk,et al.  Risperidone Compared with Both Lithium and Haloperidol in Mania: A Double‐Blind Randomized Controlled Trial , 1998, Clinical neuropharmacology.